Integrated Biopharma Stock Net Asset
Integrated Biopharma fundamentals help investors to digest information that contributes to Integrated Biopharma's financial success or failures. It also enables traders to predict the movement of Integrated OTC Stock. The fundamental analysis module provides a way to measure Integrated Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Integrated Biopharma otc stock.
Integrated |
Integrated Biopharma OTC Stock Net Asset Analysis
Integrated Biopharma's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Integrated Biopharma Net Asset | 25.25 M |
Most of Integrated Biopharma's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Integrated Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, Integrated Biopharma has a Net Asset of 25.25 M. This is much higher than that of the Personal Products sector and significantly higher than that of the Consumer Staples industry. The net asset for all United States stocks is notably lower than that of the firm.
Integrated Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Integrated Biopharma's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Integrated Biopharma could also be used in its relative valuation, which is a method of valuing Integrated Biopharma by comparing valuation metrics of similar companies.Integrated Biopharma is currently under evaluation in net asset category among its peers.
Integrated Fundamentals
Return On Equity | 0.13 | ||||
Return On Asset | 0.0336 | ||||
Profit Margin | 0.04 % | ||||
Operating Margin | 0.03 % | ||||
Current Valuation | 12.05 M | ||||
Shares Outstanding | 29.95 M | ||||
Shares Owned By Insiders | 68.58 % | ||||
Shares Owned By Institutions | 0.06 % | ||||
Price To Earning | 2.52 X | ||||
Price To Book | 0.56 X | ||||
Price To Sales | 0.21 X | ||||
Revenue | 56.25 M | ||||
Gross Profit | 6.55 M | ||||
EBITDA | 3.54 M | ||||
Net Income | 3.84 M | ||||
Cash And Equivalents | 343 K | ||||
Cash Per Share | 0.01 X | ||||
Total Debt | 53 K | ||||
Debt To Equity | 0.11 % | ||||
Current Ratio | 3.16 X | ||||
Book Value Per Share | 0.62 X | ||||
Cash Flow From Operations | 4.09 M | ||||
Earnings Per Share | 0.11 X | ||||
Number Of Employees | 147 | ||||
Beta | 0.52 | ||||
Market Capitalization | 11.2 M | ||||
Total Asset | 25.25 M | ||||
Retained Earnings | (59.89 M) | ||||
Working Capital | 913 K | ||||
Current Asset | 12.7 M | ||||
Current Liabilities | 11.79 M | ||||
Net Asset | 25.25 M |
Pair Trading with Integrated Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Integrated Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Integrated Biopharma will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Avery Dennison could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Avery Dennison when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Avery Dennison - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Avery Dennison Corp to buy it.
The correlation of Avery Dennison is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Avery Dennison moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Avery Dennison Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Avery Dennison can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Integrated OTC Stock
If you are still planning to invest in Integrated Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Integrated Biopharma's history and understand the potential risks before investing.
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |